You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ):安迪科與ImaginAb簽署相關許可協議
格隆匯 05-23 15:46

格隆匯5月23日丨東誠藥業(002675.SZ)公佈,此前披露,公司全資子公司南京江原安迪科正電子研究發展有限公司(簡稱“安迪科”)與ImaginAb, Inc.(簡稱 “ImaginAb”)簽署了《非約束性合作意向書》,達成了初步合作意向。

近日,公司收到安迪科的通知,通知其與ImaginAb, Inc.正式簽署《許可協議》。

目標產品:zirconium Zr 89 crefmirlimab berdoxam;授權內容:安迪科為獨家經銷商,將取得ImaginAb專利權下規定的權利及相關數據,進而在中國開展目標產品的開發、註冊、製造和銷售。授權區域:中國大陸、中國香港特區、中國澳門特區。

臨牀價值目標產品通過成像CD8T細胞可實現病人體內免疫細胞的可視化,以此來監測接受治療的患者體內的免疫反應,從而快速判斷癌症免疫療法的療效。該產品可用於免疫療法的臨牀研發,以加速臨牀進程;也可用做癌症病人免疫治療的療效監測手段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account